Neogen's $160M Genomics Sale: Clean Reset or Margin Rescue?

Neogen's quarter combines a loss, raised guidance, and a cleaner balance-sheet path

Neogen now has to prove that the remaining business can support a higher outlook despite posting a net loss of $17.0 million in the third quarter 2026 while still raising fiscal 2026 revenue guidance. That is a difficult mix. Bulls can argue the core business is holding up well enough to keep guidance intact. Bears can argue management is asking investors to fund a cleanup before the weaker end is fixed.

The Genomics sale improves the balance sheet, not the quarter's operating score

The balance-sheet case is straightforward. Neogen is selling Genomics for $160 million. The unit generated approximately $90 million in sales in fiscal 2025, and management says the net proceeds are expected to be used primarily for debt reduction. For a business being divested, that sale price is already close to twice revenue, so debt reduction is a logical use of the cash.

The stock, though, still depends on the operating engine. Animal Safety remains the weak spot, and that is why this quarter matters: investors need to know whether the raised guidance comes from a stronger remaining business or simply from a cleaner spreadsheet.

Core growth is improving, but Animal Safety is still the problem segment

A cleaner balance sheet only matters if the core business is stabilizing. On that score, the latest numbers suggest real progress in parts of the business, but not yet a full turnaround.

Food Safety is carrying the story

Neogen posted fiscal third quarter 2026 revenue of $211.2 million, but the more useful read was the split between segments: Food Safety core growth was 4.0%, while Animal Safety core growth was -8.7%. That points to genuine strength in Food Safety and continued weakness in Animal Safety.

You can see a similar pattern one quarter earlier. In the second quarter, reported revenue fell, but core growth increased 2.9% YoY. That suggests that, even in a tougher headline environment, the core product set still saw demand once the noisier items are stripped out.

Margin improvement gives the bull case more substance

The other encouraging sign is discipline. In the third quarter, Adjusted EBITDA margin reached 22.8%, up 110 basis points sequentially. Cash flow from operations was $22.7 million, and free cash flow was $11.1 million.

That does not erase the weakness in Animal Safety, but it does make the recovery case more credible. Management said Animal Safety was hurt by third-party supplier challenges in the quarter, which makes this look more like an operational setback than a structural collapse in demand. The key question is whether Food Safety can keep growing and margins can keep stabilizing without the weaker segment getting much worse.

The real test is whether Neogen improves without relying on transaction math

The sale is the easy part. The harder part is showing that Neogen gets better because the remaining business works better, not just because management is reshaping the portfolio.

Why bulls and bears are watching different things

Bulls have a clean case. The deal brings $160 million in proceeds, management plans to use the net proceeds primarily for debt reduction, and Neogen expects the sale to support net debt-to-adjusted EBITDA of less than three times by end of CY2026. If leverage falls and core operations hold up, the stock can start to trade on operating confidence rather than cleanup hope.

Bears have a real counter. The transaction still requires regulatory approval and customary closing conditions, and Neogen expects it to close in 2Q27. Until then, investors cannot fully count on the balance-sheet benefit. If closing slips or the market still sees leverage as too high, the clean-reset narrative weakens quickly.

What matters over the next few quarters

The next few quarters should focus on a short list of operating signals:

• Whether Food Safety maintains its core-growth lead.
• Whether Animal Safety stabilizes as supplier conditions improve.
• Whether margins and cash flow stay firm rather than reverting after one strong quarter.
• Whether the Genomics sale closes on time and delivers the expected debt-reduction benefit.

If those boxes are checked, Neogen starts to look more like a company executing a real reset. If not, the sale may look more like balance-sheet damage control than a full operating turnaround.